Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBT (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EBT for 4 consecutive years, with -$66.7 million as the latest value for Q4 2025.

  • Quarterly EBT rose 39.53% to -$66.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$195.7 million through Dec 2025, up 15.97% year-over-year, with the annual reading at -$195.7 million for FY2025, 15.97% up from the prior year.
  • EBT for Q4 2025 was -$66.7 million at Centessa Pharmaceuticals, down from -$54.7 million in the prior quarter.
  • The five-year high for EBT was -$24.7 million in Q1 2025, with the low at -$110.3 million in Q4 2024.
  • Average EBT over 4 years is -$51.4 million, with a median of -$49.3 million recorded in 2023.
  • The sharpest move saw EBT tumbled 208.97% in 2024, then skyrocketed 39.53% in 2025.
  • Over 4 years, EBT stood at -$43.8 million in 2022, then rose by 18.58% to -$35.7 million in 2023, then crashed by 208.97% to -$110.3 million in 2024, then surged by 39.53% to -$66.7 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$66.7 million, -$54.7 million, and -$49.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.